|
Variables
|
ER-Positive (N = 1048)
|
ER-Negative (N = 797)
|
|---|
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|---|
|
OR (95% CI)
|
P-value
|
OR (95% CI)
|
P-value
|
OR (95% CI)
|
P-value
|
OR (95% CI)
|
P-value
|
|---|
|
Age<35 vs. 35≤Age<50
|
1.17 (0.51–2.67)
|
0.71
|
0.41 (0.05–3.19)
|
0.39
|
1.92 (1.17–3.13)
|
0.01
|
2.54 (1.27–5.08)
|
0.01
|
|
PR-negative vs. –positive
|
1.87 (1.01–3.47)
|
0.05
|
2.00 (0.68–5.88)
|
0.21
|
1.60 (0.78–3.27)
|
0.20
|
5.45 (1.26–23.61)
|
0.02
|
|
HER2-positive vs. –negative
|
0.67 (0.33–1.37)
|
0.28
|
NI
| |
1.33 (0.82–2.16)
|
0.25
|
NI
| |
|
Proliferative index: high vs. low
|
2.30 (1.02–5.20)
|
0.05
|
3.45 (1.17–10.15)
|
0.03
|
1.00 (0.58–1.74)
|
0.99
|
1.22 (0.60–2.46)
|
0.58
|
|
Nonpalpable vs. palpable
|
3.28 (0.93–11.54)
|
0.06
|
1.61 (0.20–13.16)
|
0.66
|
2.27 (0.93–5.53)
|
0.07
|
3.95 (1.32–11.8)
|
0.01
|
- ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, CI confidence interval, NI not included in the model
